Gain Therapeutics, Inc. Common Stock GANX
i
Market datapartial · fetched 2026-11-11T14:51:59.445Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:51:22.189998593Z
FundamentalsAlpha Vantage · unavailable
Gain Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 2.00 | 369.7% | 83.6% | |||
| 30Δ | 1.94 | 422.1% | 82.8% | |||
| 35Δ | 1.88 | 474.5% | 82.0% | |||
| 40Δ | 1.82 | 526.8% | 81.2% | |||
| 45Δ | 1.76 | 579.2% | 80.4% | |||
| 50Δ | 1.69 | 631.6% | 79.6% | |||
| 55Δ | 1.63 | 684.0% | 78.8% | 1.52 | 408.8% | 15.6% |
| 60Δ | 1.57 | 736.4% | 78.0% | 1.65 | 401.2% | 13.3% |
| 65Δ | 1.51 | 788.8% | 77.2% | 1.77 | 393.6% | 11.1% |
| 70Δ | 1.90 | 386.0% | 8.8% | |||
| 75Δ | 2.25 | 412.7% | 7.1% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 2.00
- IV
- 369.7%
- B/E move
- 83.6%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 1.94
- IV
- 422.1%
- B/E move
- 82.8%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 1.88
- IV
- 474.5%
- B/E move
- 82.0%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 1.82
- IV
- 526.8%
- B/E move
- 81.2%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 1.76
- IV
- 579.2%
- B/E move
- 80.4%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 1.69
- IV
- 631.6%
- B/E move
- 79.6%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 1.63
- IV
- 684.0%
- B/E move
- 78.8%
- Pseudo strike
- 1.52
- IV
- 408.8%
- B/E move
- 15.6%
60Δ
- Pseudo strike
- 1.57
- IV
- 736.4%
- B/E move
- 78.0%
- Pseudo strike
- 1.65
- IV
- 401.2%
- B/E move
- 13.3%
65Δ
- Pseudo strike
- 1.51
- IV
- 788.8%
- B/E move
- 77.2%
- Pseudo strike
- 1.77
- IV
- 393.6%
- B/E move
- 11.1%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.90
- IV
- 386.0%
- B/E move
- 8.8%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.25
- IV
- 412.7%
- B/E move
- 7.1%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 274.40% | |
| 299.20% | |
| 196.99% | |
| 188.48% | |
| 214.53% | |
| 213.81% | |
| 187.28% | |
| 199.30% | |
| 228.48% | |
| 296.02% | |
| 232.36% | |
| 272.03% | |
| 235.65% |
Biotechnology
GENB
Generate Biomedicines, Inc. is an innovative biotechnology company at the forefront of protein therapeutics development, leveraging advanced genetic engineering and artificial…
More →GERN
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The…
More →GHRS
GH Research PLC is a pioneering clinical-stage biopharmaceutical company focused on developing psilocybin-based therapies for psychiatric and neurodegenerative disorders. The…
More →GLUE
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively…
More →GMAB
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
More →GNLX
Description unavailable
More →